Pinnacle Wealth Planning Services Inc. trimmed its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 13.5% during the first quarter, Holdings Channel reports. The firm owned 18,635 shares of the company’s stock after selling 2,907 shares during the quarter. Pinnacle Wealth Planning Services Inc.’s holdings in Takeda Pharmaceutical were worth $259,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of the company. Dorsey & Whitney Trust CO LLC boosted its position in Takeda Pharmaceutical by 4.6% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 18,197 shares of the company’s stock worth $253,000 after purchasing an additional 798 shares in the last quarter. Blair William & Co. IL boosted its position in Takeda Pharmaceutical by 6.5% during the first quarter. Blair William & Co. IL now owns 12,649 shares of the company’s stock worth $176,000 after purchasing an additional 777 shares in the last quarter. Bleakley Financial Group LLC boosted its position in Takeda Pharmaceutical by 19.1% during the first quarter. Bleakley Financial Group LLC now owns 288,535 shares of the company’s stock worth $4,008,000 after purchasing an additional 46,182 shares in the last quarter. US Bancorp DE boosted its position in Takeda Pharmaceutical by 25.3% during the first quarter. US Bancorp DE now owns 116,127 shares of the company’s stock worth $1,613,000 after purchasing an additional 23,450 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Takeda Pharmaceutical by 65.2% during the first quarter. Russell Investments Group Ltd. now owns 10,676 shares of the company’s stock worth $148,000 after purchasing an additional 4,213 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.
Takeda Pharmaceutical Price Performance
Shares of NYSE:TAK traded down $0.13 on Friday, hitting $13.36. The company had a trading volume of 4,167,467 shares, compared to its average volume of 1,572,676. The company has a current ratio of 1.11, a quick ratio of 0.58 and a debt-to-equity ratio of 0.62. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $16.39. The business has a 50 day moving average of $13.18 and a 200 day moving average of $13.81. The company has a market cap of $42.28 billion, a PE ratio of 24.29, a PEG ratio of 0.41 and a beta of 0.54.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
- Five stocks we like better than Takeda Pharmaceutical
- Where Do I Find 52-Week Highs and Lows?
- Why This AI Stock is Rising Despite Tech Sell-Off
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 7/15 – 7/19
- Earnings Per Share Calculator: How to Calculate EPS
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.